12 Pharmaceuticals Stocks to Sell Now

12 Pharmaceuticals Stocks to Sell Now

This week, the overall grades of 12 Pharmaceuticals stocks are lower, according to the Portfolio Grader database. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

Pacira Pharmaceuticals, Inc. (PCRX) is having a tough week. The company’s rating falls from a C to a D. Pacira Pharmaceuticals, Inc. is a specialty pharmaceutical company with focuses on the development, commercialization, and manufacturing of proprietary pharmaceutical products. The company also gets F’s in earnings growth, earnings revisions, and earnings momentum. For more information, get Portfolio Grader’s complete analysis of PCRX stock.

Dr. Reddy’s Laboratories Ltd. Sponsored ADR’s (RDY) rating weakens this week, dropping to a D versus last week’s C. Dr. Reddy’s Laboratories Ltd. Sponsored ADR is a global company that produces and markets active pharmaceutical ingredients, intermediates, finished dosage forms, and biologic products. For more information, get Portfolio Grader’s complete analysis of RDY stock.

Concordia Healthcare Corp. (CXRX) earns a F this week, moving down from last week’s grade of D. The company also gets F’s in operating margin growth, earnings growth, and earnings momentum. For more information, get Portfolio Grader’s complete analysis of CXRX stock.

Slipping from a C to a D rating, Intersect ENT Inc (XENT) takes a hit this week. The company also gets F’s in return on equity. For more information, get Portfolio Grader’s complete analysis of XENT stock.

This is a rough week for Relypsa, Inc. (RLYP). The company’s rating falls to D from the previous week’s C. The company also gets F’s in earnings revisions, earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of RLYP stock.

Paratek Pharmaceuticals Inc (PRTK) slips from a D to a F this week. The company also gets F’s in earnings revisions, earnings surprise, earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of PRTK stock.

Assembly Biosciences, Inc. (ASMB) declines this week from a D to a F. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of ASMB stock.

This week, Auris Medical Holding AG (EARS) drops from a C to a D rating. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of EARS stock.

Acura Pharmaceuticals, Inc. (ACUR) experiences a ratings drop this week, going from last week’s C to a D. Acura Pharmaceuticals, Inc. engages in the research, development, and manufacture of pharmaceutical product candidates utilizing its proprietary Aversion and Impede technologies. The company also gets F’s in earnings revisions, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of ACUR stock.

Pulmatrix Inc (PULM) gets weaker ratings this week as last week’s D drops to a F. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of PULM stock.

This week, BioDelivery Sciences International, Inc.’s (BDSI) rating worsens to a F from the company’s D rating a week ago. BioDelivery Sciences International, Inc. is a development-stage biotechnology company that is developing and seeking to commercialize a drug delivery technology. The company also gets F’s in earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of BDSI stock.

Merus Labs International Inc. (MSLI) experiences a ratings drop this week, going from last week’s C to a D. Merus Labs International Inc. acquires and licenses niche branded pharmaceutical products in the United States and Canada. The company also gets F’s in earnings surprise. For more information, get Portfolio Grader’s complete analysis of MSLI stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.


Article printed from InvestorPlace Media, https://investorplace.com/2016/05/12-pharmaceuticals-stocks-to-sell-now/.

©2019 InvestorPlace Media, LLC